Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced:

Results of proof-of-concept study demonstrating successful nanoforming of HER-096 into nanoparticles
Further exploration the applicability of Nanoform’s technology in the development of an oral dosage form based on HER-096 nanoparticles.
Herantis has previously shown that HER-096 penetrates the blood brain barrier (BBB) and enters the brain in therapeutic concentrations in healthy rats following subcutaneous administration. Subcutaneous administration will be used in Herantis’ HER-096 first-in-human clinical study that is expected to commence in 2023.

“Herantis remains focused on the development of HER-096 and will concentrate its efforts on getting it into clinic as soon as possible with the simple subcutaneous administration. Moreover, we are pleased to announce the collaboration with Nanoform to explore the feasibility of developing an oral dosage form of HER-096,” said Antti Vuolanto, COO of Herantis.

“We are excited that nanoforming has been successfully applied to Herantis’ HER-096 compound as well as the CDNF protein. This proof-of-concept study further validates the wide applicability of Nanoform’s technologies to a diverse range of molecules. We look forward to further nanoforming activities as HER-096 continues its development” said Christian Jones, Chief Commercial Officer of Nanoform.